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INTRODUCTION 
 The diagnosis of subclinical hypothyroidism is mostly 
biochemical as most of the patients have a serum thyroid stimulating 
hormone above the normal reference range and serum free and total 
thyroxine T4 and T3 are normal. Most of the patients with subclinical 
hypothyroidism have few or no signs of thyroid dysfunction. The normal 
reference range of TSH was 0.45 – 4.5mU/l.(2,10)The overall percentage 
range from 5 to 10% in large screening population. The prevalence is 7 to 
26% in studies conducted in elderly. Since the hormone levels are normal 
there comes a confusion between compensated hypothyroidism and 
euthyroid state.(3,14) 
 Subclinical hypothyroidism is more common in women. Among 
patients with subclinical hypothyroidism 80% have TSH of less than 
10mIU/l. The most notable consequence of subclinical hypothyroidism is 
its high chance of transformation to true hypothyroidism. It is also 
associated with dyslipidemia and adverse cardiovascular risk profile. Now 
the recent practical approach of treatment of subclinical hypothyroidism is 
levothyroxine therapy for persons with serum TSH of more than 10mIU/L 
and the therapy is individualised for patients with a TSH value of less than 
 10mIU/L. (2,10) 
 Subclinical hypothyroidism is a common endocrine problem 
with 3 to 8% prevalence among general population. Antithyroid antibodies 
are positive in 80% of patients with SCH. Prior radioiodine therapy, 
external neck and head irradiation may cause mild form of thyroid 
dysfunction.(2,10) Transient elevation of TSH VALUES may occur after 
episodes of postpartum thyroiditis. Due to recent increasing prevalence of 
SCH and metabolic risk factors such as adverse cardiac function and 
hyperlipidemia, the AMERICAN THYROID ASSOCIATION has 
recommended the importance of screening by assessment of serum TSH 
values above the age of 35 years and followed up every 5 years later. 
Because of high likelihood of SCH to cause complications during 
pregnancy and brain development of fetus, screening of pregnant women 
for subclinical hypothyroidism is suggested. (2,10) 
 “In the conclusions of Whickham survey, the risk of acquiring 
hypothyroidism was 4.3% per year in women in a year, if both the levels 
serum TSH and anti-thyroid antibodies were found to be elevated, 2.6% 
chance in patients with elevated TSH alone, and 2.1% chance per year with 
positive anti-thyroid antibodies alone.”On follow up of the course of 
patients with subclinical hypothyroidism, a recent prospective study by 
Gerold Huber and team concluded that high risk factors for progression to 
 overt hypothyroidism were base line TSH >12uIU/mL, reduced thyroid 
reserve and positive for thyroid peroxidise antibody .So treatment of  
subclinical hypothyroidism holds good in various situations and in 
prevention of conversion to overt hypothyroidism.(14) 
 
 
 
 
  
 
 
AIM OF THE STUDY 
 
 TO ASSESS LIPID PROFILE ABNORMALITIES IN PATIENTS 
DIAGNOSED WITH SUBCLINICAL HYPOTHYROIDISM 
  
  
REVIEW OF LITERATURE 
SUBCLINICAL HYPOTHYROIDISM 
 Subclinical hypothyroidism denotes mild thyroid dysfunction. 
Its prevalence in general population is around 5 to15 % of patients. Risk of 
transformation to true hypothyroidism is 2 to 5 % per year. The best 
screening test for any thyroid disorder is measurement of TSH. It is highly 
a sensitive and specific test. Serum TSH has log relationship with hormone 
serum thyroxine, so if serum thyroxine levels doubles there is a 
hundredfold change in seum TSH levels. (2,10) 
         Serum TSH levels show variation with respect to race, age and 
iodine intake. “Most of the circulating t3 is formed by peripheral 
conversion of t4 by enzymatic   removal of an iodine atom from t4. Very 
little t3 is produced by the thyroid gland itself. T3 is the active form of 
hormone and binds to thyroid hormone receptors in target cell nuclei to 
initiate various physiological functions.”(2,10). Data on health related 
quality of life and symptoms did not show significant differences between 
intervention groups. Some evidence indicates that levothyroxine improves 
some parameters of lipid profile and left ventricular function. 
 
 EPIDEMIOLOGY; 
 Prevalence of subclinical hypothyroidism is around 10 to 15 % 
in different studies. It is said to have increased prevalence among female 
gender, caucasians and iodine sufficient areas. The levels of TSH is also 
higher in obese patients, the level being directly proportional to the BMI. It 
is seen more commonly in females. After the sixth decade men and women 
has equal prevalence. The total prevalence of subclinical hypothyroidism 
in general population is 10 to 15%. Higher prevalence is seen in white than 
black(10,13,14). The whickham survey in the north east of england 
reported that 7.5% 0f women and 2.5% of men have TSH levels have > 
6.0mIU/l. The NHANES III study of united states reported serum TSH 
levels more than 4.6mu/l in 4.5% of the population. The colorado study 
showed raised TSH ranging between 5.0 to 10 mu/l in 9.5% of population. 
The prevalence of subclinical hypothyroidism in elderly women over 65 
years was 17.4% among general population.(3,14) 
 The framingham study and dutch study analysis has confirmed 
that subclinical hypothyroidism has got higher prevalence among elderly 
population over 60 years. The prevalence was 8.2% in men and 16.9% 
among women. The iodine intake has no relation to the prevalence of 
subclinical hypothyroidism and its prevalence seems to be little higher in 
areas of high iodine intake rather than low salt intake areas. (3,14) 
  It has got higher prevalence in patients with down syndrome, 
type 1 diabetes mellitus and other autoimmune diseases. Pregnant women 
in US had 2% prevalence of subclinical hypothyroidism of which 58% had 
positive anti TPO antibodies. One study with 1250 populations aged over 
60 years showed the prevalence of subclinical hypothyroidism in 11.6% of 
women and 3% of men. Antithyroid antibodies were positive in significant 
titres in 46% of those with serum TSH levels between 5 and 10 mIU/l and 
81% of those with serum TSH greater than 10mIU/l.(2,10) 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 NATURAL HISTORY 
 Subclinical form of hypothyroidism represents mild thyroid 
dysfunction which has high likelihood of transformation to true 
hypothyroidism. In a year, transformation to true hypothyroidism is 
reported to be 3 to 18 %. In a follow up study consisting of 154 female 
patients , over a longer period of 10 years duration  57% of them retained 
to be SCH patients and 34% showed transformation to true hypothyroidism 
and only 9% of patients reverted back to normal TSH levels The strongest 
predictors for progression are the presence of antithyroid antibodies, serum 
TSH values greater than 20mIU/L, history of radioiodine ablation for 
graves, history of external irradiation for nonthyroidal illness and chronic 
lithium treatment.(3,14) 
In a New Mexico study of asymptomatic ambulatory subjects with 
subclinical hypothyroidism older than 60 years, one third developed overt 
hypothyroidism during 4 years of follow-up; among them were all those 
whose initial serum TSH concentrations were higher than 20 uIU/mL .In a 
study where patients with subclinical hypothyroidism where followed for 8 
years, showed that 53% of them turned out to overt hypothyroidism and 
47% continued to be in subclinical range. Most of them who turned out to 
be overt hypothyroidism had autoimmune etiology and exposure to prior 
external radiotherapy and radioiodine therapy.(2,10) 
  
 
 
 
  
 IMPORTANCE; 
It is necessary to treat patients with subclinical hypothyroidism if 
the biochemistry is sustained in patients with a past history of radioiodine 
treatment and positive for antithyroid antibodies. Treatment is essential in 
these patients because risk of progression to hypothyroidism is inevitable. 
Except in pregnancy where there is an immediate need for initiation, in 
most of the circumstances the disorder should be reconfirmed after 2 to 3 
months. It has high risk for progression to heart failure and CAD. The 
initiation of treatment depends on age of the patient, level of TSH, and the 
presence of autoantibodies.(2,10,14) 
 
ETIOLOGY: 
“HASHIMOTO THYROIDITIS, an autoimmune form of thyroiditis 
is the commonest etiology of the disease subclinical hypothyroidism.” In 
patients with prior history of radioiodine therapy for hyperthyroidism, 
subclinical hypothyroidism precedes overt thyroid failure. Subclinical 
hypothyroidism precedes overt hypothyroidism in patients who have 
undergone partial thyroidectomy for hyperthyroidism or nodular goitre. 
Other form of autoimmune diseases like type1 diabetes mellitus, Addison 
disease, down syndrome and turner syndrome are associated with 
increased probability of transformation to both subclinical and overt 
hypothyroidism of autoimmune etiology.(3,14) 
 Subclinical hypothyroidism is also identified during first trimester 
of pregnancy with positive anithyroid antibodies. The risk of developing 
postpartum thyroiditis or overt hypothyroidism depends largely on 
antibody status and titre. Subclinical hypothyroidism is also seen in 
patients with prior external radiotherapy to head and neck.(3,14) 
Nonthyroidal illness is associated with transient increase in levels of serum 
TSH especially in the recovery phase of critical illness. Drugs like lithium 
and amiodarone and radiocontrast agents are associated with increased risk 
of subclinical hypothyroidism.(2,10) 
 
EFFECTS OF SUBCLICAL HYPOTHYROIDISM: 
Several randomised control trials have observed rise in serum total 
cholesterol, serum LDL levels and serum triglceride levels in patients with 
subclinical hypothyroidism. It has got strong association with females 
,increasing age, and those with baseline TSH >12mu/l . trials also showed 
correction of dyslipidemia on treatment of hypothyroidism.(2,10) 
 
While intima and media thickness, endothelial dysfunction 
decreased systolic and diastolic dysfunction and dyslipidemia are all 
associated with subclinical hypothyroidism, this association and impact of 
treatment on cardiovascular outcome is limited and not constant. Variable 
 association is seen with prevalence of heart failure and progression to 
subclinical hypothyroidism. Cardiovascular morbidity and mortality is 
higher with TSH levels more than 10 mIU/l.(2,3,10) 
 
Myocardial structure and contractility largely varies in relation to 
subclinical TSH level. Increased peripheral vascular resistance and 
diastolic dysfunction is seen in some patients with subclinical 
hypothyroidism. The cardiac function which means increased cardiac 
output and decreased peripheral resistance is seen after treatment with 
thyroxine. Few studies showed improvement in right ventricular systolic 
and diastolic function with thyroxine. (15,16) 
 
The cardiovascular morbidity and mortality in subclinical 
hypothyroidism was illustrated by a flow mediated dilatation .This is a 
measure of vascular endothelial response and an early marker of 
atherosclerosis. It was impaired in patients with subclinical 
hypothyroidism against euthyroid controls. The branchial-ankle pulse 
velocity was significantly increased in patients with subclinical 
hypothyroidism. Also it was seen in some studies, patient with subclinical 
hypothyroidism had increased central aortic pressure and arterial stiffness. 
serum C reactive protein was increased in patient with subclinical 
 hypothyroidism which normalised with treatment. Treatment with 
thyroxine also seem to increase the HDL associated  PAF-AH activity ( 
platelet activating factor acetyl hydrolase) in patients with subclinical 
hypothyroidism.(5,15,16) 
 
Many studies has shown increased prevalence of cardiovascular 
morbidity with subclinical hypothyroidism. In contrast to the above 
mentioned studies, the cardiovascular health study of population aged 
above 60 years illustrated no specific association of cardiovascular 
morbidity with subclinical hypothyroidism.(4,17) 
 
LIPID ABNORMALITIES IN SUBCLINICAL  
HYPOTHYROIDISM. 
 
 “ In patients with subclinical hypothyroidism , large cross sectional 
studies showed that modest elevations of serum TSH (between 5.1 and 
10mIU/l) had significantly elevated total cholesterol values compared with 
euthyroid individuals. Consistent changes in other lipid parameters like 
serum LDL, serum HDL, serum triglyceride level was not appreciated. 
Some studies with subclinical hypothyroidism showed abnormal lipid 
profile with elevated LDL levels and decreased  serum HDL levels.” 
 Some studies showed higher levels of serum apoprotein A1and serum 
lipoprotein A levels. “In a randomised control trial, patients with 
subclinical hypothyroidism treated with thyroxine showed significant 
lowering of total cholesterol and serum LDL levels (18,19)”. A 
metaanalysis in patients with subclinical hypothyroidism showed 
significant reduction in total cholesterol levels, without much significant 
change in serum HDL and triglyceride levels. The lowering of serum 
cholesterol was noticed in patients with levels more than 240mg/dl .(21) 
 
NEUROPSYCHIATRIC MANIFESTATIONS: 
Analysis of reports has showed increased prevalence of depression  
and bipolar affective disorder in patients with subclinical hypothyroidism. 
But the study is limited because of inadequate control groups, lithium 
therapy, patients with increased response to serum TSH ,administration of 
TRH or high levels serum antithyroid antibodies.(22) Some studies 
revealed the prevalence of 14.8% of hypothyroidism in patients with 
neurotic depression. Higher prevalence of panic disorder and poor 
response to antidepressant therapy was seen in patients with subclinical 
hypothyroidism and depression. Those diagnosed with subclinical  
hypothyroidism has  increased  risk  of  developing anxiety, somatic 
complaints, depressive features, and hysteria in comparison to euthyroid 
 women. Improvements in neuropsychiatric manifestations are seen with 
appropriate treatment with thyroxine.(8,21,22) 
 
Evaluation of patients with euthyroid, hypothyroidism, and 
hyperthyroidism to measure brain function using BRAIN MRI with widely 
used “digit -n-back working memory task.” Same functions were carried 
out after treatment with thyroxine. Significantly low score of brain 
function was seen with hypothyroidism and subclinical hypothyroidism 
compared to euthyroid state. Evaluation was done in areas like “common 
frontoparietal network, bilateral dorsolateral prefrontal cortex, bilateral 
premotor areas, supplementary motor area, anterior cingulate cortex and 
bilateral parietal areas.” The load effect of BOLD response( blood oxygen 
level dependant)was found only in bilateral parietal and premotor cortex. 
The same patients exhibited some load effects in all five areas after 
treatment with thyroxine. These analysis concluded impairment of 
working memory in subclinical hypothyroidism. Also treatment with 
l-thyroxine showed improvement in memory performance and frontal 
executive functions.(23,24) 
 
  
 IMPACT ON PREGNANCY AND FERTILITY: 
 “Subclinical hypothyroidism undetected during pregnancy 
adversely affect the survival and neuropsychological development of fetus 
Normally the requirement of thyroxine in pregnancy increases by 45% as 
the levels of thyroid binding globulin increases. In children of subclinical 
hypothyroidism aged 7 to 9 years showed a 7 point reduction in intelligent 
quotient compared with euthyroid mothers. So this suggest the importance 
of screening of pregnant women for hypothyroidism and treatment of 
subclinical hypothyroidism.”(24) 
 
NEUROMUSCULAR DYSFUNCTION: 
Patients with subclinical hypothyroidism may develop significant 
neuromuscular dysfunction. This is seen with TSH levels usually greater 
than 10mIU/l. The neuromuscular dysfunction reverses on treatment with 
treatment with thyroxine.(10) 
 
Infertility and ovulatory dysfunction has higher association with 
subclinical hypothyroidism. Hypothyroidism is associated with higher 
prevalence of infertility from anovulation. Increased risk of abortion are 
seen with pregnant women with overt hypothyroidism. Spontaneous 
abortion of 10% was seen in pregnant females with subclinical 
 hypothyroidism with elevated antithyroid peroxidise and antithyroglobulin 
antibodies. Luteal phase dysfunction, anovulatory cycles and menorrhagia 
are seen with subclinical hypothyroidism which results in infertility. The 
outcome of pregnancy in patients with hypothyroidism on adequate 
treatment and inadequate therapy was compared. Those who received 
adequate therapy, the complications during pregnancy was minimal.(22) 
 
SPECIAL SITUATIONS: 
 Transient elevation in levels of serum TSH levels was seen in 
patients with critical illness during recovery phase and these patients 
should be revaluated as subclinical hypothyroidism in hospitalised 
patients with elevated TSH leves may be invalid. 
 Assay variability seen with diurnal variation shows elevated serum 
TSH levels due to robust pulse of TSH secretion especially at night. 
 Heterophile antibodies might interfere with TSH measurement. 
 Adrenal insufficiency is associated with elevated with TSH levels. 
 TSH secreting pituitary adenomas 
 Resistance to thyroid hormone 
 Metoclopramide or domperidone therapy.(1,7,9) 
  
 SCREENING OF THYROID DISEASE: 
“The following categories of patients should be screened for thyroid 
disease. 
Patients with atrial fibrillation or hyperlipidemia 
 Periodic assessment in patients receiving amiodarone and 
lithium 
 Annual check of TFT in diabetic patients 
 Females with type 1 diabetes in first trimester of pregnancy 
and post delivery (because of 3 fold increase in incidence of 
postpartum thyroid dysfunction) 
 Females with past history of postpartum thyroiditis. 
 Annual check of  thyroid function in patients with down 
syndrome, turner syndrome and Addison disease. 
 Females with thyroid autoantibodies 
 Maternal thyroid antibodies associated with miscarriage and 
preterm delivery. “(1,2,3,4) 
 
 
 
 
 
  
  
  
 
  
  
 
  
 HYPOTHYROIDISM: 
              Hypothyroidism results from varied abnormalities that cause 
insufficient secretion of thyroid hormones. The most common cause is 
autoimmune thyroiditis. Myxoedema is  called a severe form of thyroid 
disorder in which there is accumulation of hydrophilic mucopolys 
accharides in the ground substance of dermis and other connective tissue . 
It leads to thickening of facial features and a induration of skin. (1,6,4) 
.Other hormones like somatostatin glucocorticoids, cytokines like 
interleukin 1and TNF alpha, drugs like phenytoin and dopamine suppress 
the TSH secretion . TSH and TRH secretion is inhibited by T4, forming a 
negative feedback loop that maintains free T4 within the normal reference 
range. While  T4 is exclusively secreted by the thyroid gland, about 80% 
of T3, which is the active hormone, is generated by 5’monoiodination of 
T4.(1,2) 
 
THYROID HORMONE TRANSPORT AND ACTION 
Thyroid hormone exists in both free and bound form in circulation. 
About 80% of the hormone is bound to thyroxine binding globulin .Other 
proteins to which thyroid hormone is bound are transthyretin (TTR), and 
albumin. Only the free form of thyroxine enters cells and produces 
biological effect. 
 After binding to a nuclear DNA bound thyroid hormone receptor 
(TR), for which hormone T3 has a 15-fold high binding affinity compared 
to T4.There are two TR genes, TRα and TRβ. The coded protein has three 
major functional domains, one to bind ligand, one to bind DNA, and the 
other for transcriptional activation.(1.3) 
 
Iodide present in the plasma is taken up via active transport into the 
thyroid follicular cells, a process which becomes more evident in the 
iodine deficiency state. Iodine deficiency results in enlargement of the 
thyroid to enhance the ability of the glands to trap iodine. The term 
endemic goitre is used to define goitre seen in a population with iodine 
deficiency. An area is defined to be endemic if more than 5% of children, 
in the age group between 6 to 12 years , are found to have goitre. (1,2,3,4) 
 
The stages of goitre formation include an initial diffuse 
parenchymatous goitre, followed by diffuse colloid goitre, hyperplastic 
nodular goitre, nodular parenchymatous goitre and nodular colloid goitre. 
The first two stages of autoimmune are found to disappear after making 
region iodine replete, while later stages of thyroiditis are unlikely to 
involute. Other manifestations of iodine deficiency depend on these verity 
and age at exposure. Endemic cretinism is a state of severe congenital 
 hypothyroidism occurring in an endemic area. Two clinical types are 
recognised: (1,2)neurological cretinism, characterised by mental 
retardation, abnormal speech and hearing, diplegia, and strabismus; 
myxoedematous type. It is further characterised by prominent features of 
hypothyroidism, mental retardation and short stature. Learning disability 
has been described even in euthyroid children living in endemic areas. 
During pregnancy exposure to iodine deficiency  is also highly associated 
with complications like abortions, stillbirths, increased foetal anomalies 
and perinatal mortality. It is necessary to create awareness to people by 
health education for consumption of iodated salt .(1) 
 
AUTOIMMUNE THYROIDITIS 
“Autoimmune form of thyroid disease evolves in a stepwise 
manner first presenting as hashimoto’s type of thyroiditis and ultimately 
transforming at later stages to atrophic form of thyroiditisue to damage to 
the thyroid tissue. This causes a compensatory increase in the level of 
thyroid stimulating hormone to maintain normal thyroid hormone levels 
.This state of condition at which at which patients are asymptomatic, but 
still the TSH levels are quite high is called subclinical hypothyroidism. 
As the disease progresses, T4 level decreases and TSH level increases 
further. At this stage of disease, symptoms suggestive of hypothyroidism 
 becomes evident especially with TSH levels more than 10 mIU/l. this 
clearly, marks transition from subclinical to overt 
hypothyroidism.”(1,2,4,5) 
 
Prevalence:   
Autoimmune form of hypothyroidism has an annual incidence of 4 
per 1000 among female population and 3 per 1000 among male 
population. It is found to be more commonly prevalent in japan, most 
likely relating to dietary exposure to high iodine intake and certain 
genetic correlation. The prevalence of hypothyroidism increases as age 
increases. The statistically analysed mean age group for prevalence is 60 
years.(1,5,6) 
 
The incidence of subclinical hypothyroidism is roughly around 8 to 
10 % among women and 3% among males. The risk of progression from 
subclinical hypothyroidism to overt hypothyroidism is 4% annually. This 
transformation is more common when subclinical hypothyroidism is 
associated with positive antithyroid antibodies. 
 
“Hashimoto’s thyroiditis is characterized by marked lymphocytic 
infiltration of the thyroid, germinal center formation , thyroid follicles 
 atropy, oxyphil metaplasia, absence of colloid, and mild to moderate 
fibrosis. In atrophic thyroiditis, there is much more extensive fibrosis, 
lymphocyte infiltration is less pronounced, and thyroid follicles are 
almost completely absent. A weak association also exists between 
polymorphisms in CTLA-4, a T cell–regulatory gene, and autoimmune 
hypothyroidism. Both of these genetic associations are shared by other 
autoimmune diseases, which may explain the relationship between 
autoimmune hypothyroidism and other autoimmune diseases, especially 
type 1 diabetes mellitus, Addison’s disease, pernicious anemia, and 
vitiligo.“(1,2,4,11) 
 
There is association between autoimmune form of hypothyroidism 
and down’ syndrome relating to a gene on the chromosome 21. The 
association of autoimmune hypothyroidism with turner syndrome is 
related to X chromosome related genetic factor. High dietary iodine 
intake and decreased exposure of children to infection and microorganism 
has high risk of developing autoimmune hypothyroidism.(2,3,6,13) 
 
Clinically significant markers of autoimmune hypothyroidism are 
antibodies to thyroid peroxidase and thyroglobulin .Autoimmune 
hypothyroidism is characterised by complement mediated attack complex 
 by the fixation of complement by TPO antibodies. Transplacental transfer 
of these antibodies TPO and thyroglobulin have no role in fetal 
hypothyroidism. Among autoimmune hypothyroidism, TSH-R antibodies 
are found to be positive in 20%. This results in hypothyroidism especially 
among Asian population. In this case, the transplacental transfer of 
antibodies causes transient neonatal hypothyroidism. (2,4,12) 
 
PRESENTATION OF SUBCLINICAL HYPOTHYROIDISM 
       SYMPTOMS: 
 Dry course skin 
 Decreased perspiration 
 Puffiness of face  
 Skin thickening without obvious pitting 
 Pallor 
 Yellowish discoloration of skin due to 
hypercarotenemia 
 Brittle and dry hair 
 Alopecia 
 Madarosis 
 Constipation 
 Weight gain despite of poor appetite 
  Cold intolerance 
 Loss of libido 
 Amenorrhoea and oligomenorrhoea 
 Infertility and miscarriages 
         SIGNS: 
 Bradycardia 
 Increased distolic BP 
 Cool extremities 
 Sleep apnoea 
 Serous cavity effusions like pleural and pericardial 
effusions 
 Carpal tunnel syndromes 
 Delayed relaxation of tendon reflexes 
 Memory disturbances.(4,3,6) 
 
TREATMENT OF HYPOTHYROIDISM: 
The standard daily replacement doseof oral levothyroxine is 
usually around 1.6 μg/kg body weight (typically 100–150 μg), to be 
ideally taken at least 30 min before breakfast.(2,3,4).“Adult hypothyroid 
patients under 60 years old, with no evidence of heart disease may be 
started on 50–100 μg of oral levothyroxine (T4) daily. The dose is 
 adjusted accordingly on the basis of TSH levels, with the treatment goal 
of achieving normal TSH. The treatment responses are gradual and 
should be measured about 2 months following treatment or after any 
subsequent dosage change in levothyroxine dosage. The clinical effects of 
replacement of levothyroxine are slow to appear. Patients might not 
experience full relief from symptoms till 3–6 months after the normal 
TSH levels are restored. Adjustment of levothyroxine dosage should be 
made in 12.5- or 25-μg increments if the TSH is still found to be high; 
Decrements of the same magnitude has to be made if the TSH level is 
further suppressed. (2,4) 
 
Serum T4 has a half life of 7 days . On missing a dose of tablet , 
patients are advised to take 2 tablets at a time .sometimes patients require 
high doses of thyroxine; 
 Malabsorption 
 Estrogen or hormone replacement therapy 
 Heavy meals  
 Drugs interfering with its metabolism like 
anticon vulasants {carbamezepina and 
phenytoin}, calcium and iron supplements, 
Proton pump inhibitors, lovastatin, 
amiodarone and rifampicin etc. (1,2,3) 
 
 “Treatment of subclinical hypothyroidism is indicated to prevent 
progression of disease to overt hypothyroidism in patients with elevated 
serum TSH levels more than 10mIU/l and presence of high titres of serum 
anti TPO antibodies. Only 5 % of subclinical levels of TSH return to 
normal without treatment. Presence of obvious goiter also warrants 
treatment. The major practical benefit of initiation of treatment in 
subclinical hypothyroidism is improvement of symptoms, cognitive 
function like memory, lowering of levels of serum total cholesterol and 
serum LDL levels. Also treatment significantly improves cardiac function 
like myocardial contractility.”(1,2,25) 
 
There is no universally accepted recommendations for the 
management of subclinical hypothyroidism. Treatment with 
levothyroxine is recommended when the patient is a woman and if she 
wishes to conceive or is already pregnant, or when TSH levels are above 
10 mIU/L. When serum TSH levels are below10 mIU/L, treatment with 
thyroxine should be considered when patients have symptoms suggestive 
of hypothyroidism, presence of positive TPO antibodies, or evidence of 
heart disease. It is important to confirm that any elevation of TSH is 
sustained over a 3-month period before treatment is given. Treatment is 
initiated with a starting low dose of levothyroxine (25–50 μg/d) with the 
 goal of normalizing TSH. If levothyroxine is not given, thyroid function 
should be evaluated and followed up annually.(2,10,25) 
 
TREATMENT GUIDELINES: 
TSH BETWEEN 4.5 AND 10 mIU/l ; 
Although there is no conclusive evidence to show reduction in 
symptoms and lipid profile abnormalities in any randomised control trials 
with levothyroxine therapy, it might prevent transformation to true 
disease. There is  no proper analysis to show the benefits of early 
therapy of subclinical disease compared with treatment of patients after 
the development of symptoms.(2,4,25) 
 
So therapy of this group of patients with levothyroxine has to be 
individualised and it largely depends on the following issues; 
 Degree of TSH elevation 
 Age of the patient 
 Associated medical illness 
 Persistent and gradual increase in TSH on follow up. 
 Presence of goitre 
 Presence of antithyroid antibodies 
 Symptoms suggestive with hypothyroidism 
  So for patients with TSH levels between 4.5 and 10 mIU/l , routine 
treatment with levothyroxine is not advisable. It is essential to follow up 
such patients with thyroid function testing at 6 to 12 months interval for 
evaluating the progression of the disease.(25) 
  
 Considering the intelligent quotient of women with subclinical 
hypothyroidism during pregnancy and the effect of thyroxine on the 
neuropsychiatric development and growth of the patient, treatment of 
children and adolescent children and pregnant females with elevated TSH 
has become a prime indication. Some patients with subclinical 
hypothyroidism present with symptoms compatible with hypothyroidism 
and therapy may be initiated and continued for several months trial with 
monitoring of symptomatic improvement. Further continuation of 
treatment with thyroxine depend on symptomatic benefits.(25,4,2,3) 
 
TSH LEVELS MORE THAN 10mIL/l; 
This group of patients benefit much from levothyroxine therapy. 
The factors that determine the response of lipid profile abnormalities to 
thyroxine therapy are higher levels of TSH and high levels of total 
cholesterol and hypertriglyceridemia. Evidence based study proves 
worsening of bipolar disorder and depression with mild thyroid failure. It 
 may also alter the pattern of nerve conduction, muscle function and 
cardiac contractility. Treatment with levothyroxine might cause 
symptomatic improvement in these patients.(4,25) 
 
Treatment is initiated if TSH is more than 10 mIU/L in following 
situations: 
 Higher TSH levels on repeated measurements 
 Presence of signs and symptoms 
 Family history of thyroid disorder 
 Pregnant females 
 Severe hyperlipidemia 
 Infertility 
 Insulin resistance 
 Tobacco usage 
 Morbid obesity(2,3) 
 
Start therapy with low dose of 50 to 75microgram per day .Lower 
doses of 12.5 to 25 microgram per day should be used in patients with 
coronary artery disease. Patient should be followed up 4 to 6 weeks 
following therapy with serum TSH levels and the dosage can be changed 
accordingly and then followed up yearly to achieve appropriate serum 
TSH level (2,3,7) 
 Controversies regarding treatment of subclinical hypothyroidism: 
 Cost of therapy 
 Cost of monitoring with TFT 
 Lifelong compliance to daily therapy especially in 
asymptomatic patients 
 Exacerbation of angina and arrhythmias(2,10,14) 
  
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
  
 
AIMS AND OBJECTIVES 
• To assess the lipid profile abnormalities in patients with subclinical 
hypothyroidism. 
 
 
 MATERIALS AND METHODS 
Source of the data 
This  study is a hospital based cross sectional study performed  in 
Government kilpauk medical Hospital. All patients who fitted the 
biochemical evidence for subclinical hypothyroidism and the inclusion, 
exclusion criteria were included in the study. None of the patients were 
part of a routine screening programme. 
 
Design of study 
Cross sectional, comparative study 
 
Period of study 
8 months 
 
Sample size 
96 
 
Ethical committee approval :obtained 
Consent :Informed consent obtained 
Financial support : Nil 
Conflict of interest : Nil 
 Collaborating department: 
Department of endocrinology 
Department of general surgery and ostretics & gynaecology. 
 
Selection of study subjects 
• Inclusion criteria 
All newly detected  cases of subclinical hypothyroidism { normal t3, t4  
, free t4 and TSH > 5.5 mU/L} 
 
• Exclusion criteria 
1. Patients aged twelve or less. 
2. Patients on thyroxine 
3. Known case of diabetes and hypertension  
4. Chronic renal failure 
5. Chronic liver disease 
6. Primary adrenal failure 
7. On drugs like beta blockers ,diuretics, steroids, OCP,  
8. Patients already on hypolipidemic drugs.  
 
 
 
 Applying the sample size formula : 
               N=Z^2{P*Q}/ l^2 
 Z; with 95% confidence interval 
 P: prevalence of subclinical hypothyroidism 
 Q: 100-p 
 L: relative precision is 50% 
 
So on applying this formula my sample size was around 96 
  
  
 
JUSTIFICATION OF STUDY 
  
The prevalence of subclinical hypothyroidism is on increasing trend 
especially among females and pregnant women. It also has close 
association with the metabolic syndrome. The two most important 
complications of ignoring subclinical hypothyroidism with treatment 
might result in dyslipidemia and adverse cardiac function. So early 
diagnosis of dyslipidemia in subclinical hypothyroidism and its treatment 
with thyroxine helps to reduce cardiovascular complications and 
morbidity. 
 
 METHOD OF THE STUDY: 
 
Cases were selected from patients presenting to general medicine 
op, general surgery op, endocrinology op and obstretics and gynaecology 
op. Patients presenting to these op with vague complaints of obesity, recent 
gain of weight, tiredness, coarse facial features, hair loss, dry skin, 
infertility, voice changes, memory disturbance, cognitive dysfunction, 
mood disorders, swelling of neck, menstrual irregularities are selected. 
They are screened for subclinical hypothyroidism by doing fasting TFT 
comprising freeT4, freeT3 and TSH and fasting lipid profile is also done 
for the patient. Among the 620 patients screened for subclincal 
hypothyroidism, 96 turned out to have the disease. 
 
All pregnant females are screened with TFT. Patients are selected 
after they fit into the inclusion and exclusion criteria. Clinical data 
comprises of thorough symptomatic analysis and physical examination and 
detailed history regarding past illness and drug intake. Laboratory analysis 
of blood urea, serum creatinine, TFT comprising of free T3, free T4, and 
TSH. And fasting lipid profile. In our college, thyroid function test was 
done using ELISA and lipid profile using enzymatic kit method. 
 
 SAFETY:  
 No harm done to the patient  
 No extra expenses for the patient 
 Informed consent was obtained 
 
LIMITATIONS OF THE STUDY 
Sample size was achieved with less absolute precision, hence the results 
of the study will have wide variability. Due to limited resources and 
practical constraints this study is being carried out with a small sample 
size. Thus the appropriate representation of the population and better 
outcomes could be attained by increasing the sample size 
  
  
RESULTS 
STATISTICAL TOOLS: 
The collected data was analysed with SPSS 16.0 version. To 
describe about the data descriptive statistics, frequency analysis, 
percentage analysis were used for categorical variables and the mean & 
S.D were used for continuous variables. To assess the relationship between 
the variables Pearson's Correlation was used. To find the significance in 
categorical data Chi-Square test was used. In both the above statistical 
tools the probability value .05 is considered as significant level.  
Using this computer software, multiple variables like mean range 
percentages, standard deviation, chi square and p value etc are used to test 
for the statistical significance of the study. A p value of  less than 0.05 
denotes significant relationship. 
 
 
  
 PROFILE OF THE STUDY CASES: 
TABLE 1 :  SEX DISTRIBUTION. 
 
SEX Frequency Percent 
 Female 88 91.7 
Male 8 8.3 
Total 96 100.0 
 
 
 
 
Of  the 96 cases, 88  cases( 91.7%) were females and 8 cases 
(8.3%) were males 
Female 
92% 
Male 
8% 
Gender Distribution 
 TABLE 2: 
AGE DISTRIBUTION: 
 
 
 
Among the  96 patients ranging from 11 years to 60 years with 
maximum 33% were between 46 to 55 years. The mean age was 41.3 
years.  
0 
5 
10 
15 
20 
25 
30 
35 
< 25 yrs 26 - 35 yrs 36 - 45 yrs 46 - 55 yrs Above 55 
yrs 
10 
15 
30 
32 
9 
Age range 
               AGE Frequency Percent 
 < 25 yrs 10 10.4 
26 - 35 yrs 15 15.6 
36 - 45 yrs 30 31.3 
46 - 55 yrs 32 33.3 
Above 55 yrs 9 9.4 
Total 96 100.0 
 TABLE 3: 
BMI DISTRIBUTION: 
 
           BMI Frequency Percent 
 Lean 24 25.0 
Normal 59 61.5 
Obese 13 13.5 
Total 96 100.0 
 
Lean - <20 kg/m^2 
Normal -20 to 25 kg/m^2 
Obese- >25 kg/m^2                            
 
 
Majority of cases around 61% were having normal BMI ranging 
from 20 to 25 kg/m^2. 
Lean 
25% 
Non Obese 
61% 
Obese 
14% 
BMI range 
 TABLE 4; 
TSH DISTRIBUTION: 
                TSH Frequency Percent 
 < 10 47 49.0 
10 - 20 33 34.4 
> 20 16 16.7 
Total 96 100.0 
 
 
 
Among  the  96 cases the mean TSH value was 12.3 mIU/l ranging  
between 5.8 and 25 mIU/l. 49% of cases were having TSH between 5.5 and 
10mIU/l and 34% were having TSH between 10 to 20 mIU/l. 
  
< 10 
49% 
10 - 20 
34% 
> 20 
17% 
TSH range 
  
TABLE 5: 
TOTAL CHOLESTEROL DISTRIBUTION: 
 
TOTAL CHOLESTEROL Frequency Percent 
 Normal 39 40.6 
Borderline 18 18.8 
High 39 40.6 
Total 96 100.0 
 
 
 
Normal: < 200mg/dl 
Borderline:201 to 239 mg/dl 
High: > 240mg/dl 
  
  
 
TABLE 6: 
LDL DISTRIBUTION: 
 
                    LDL Frequency Percent 
 Normal 41 42.7 
Borderline 14 14.6 
High 41 42.7 
Total 96 100.0 
 
 
Ldl values 
Normal: < 130mg/dl 
Borderline: 131 to 159 mg/dl 
High: >160 mg/dl 
  
 TABLE 7: 
TRIGLYCERIDE DISTRIBUTION: 
 
Triglyceride Frequency Percent 
 Normal 70 72.9 
Borderline 16 16.7 
High 10 10.4 
Total 96 100.0 
 
 
 
Normal: <150 mg/dl 
Borderline: 151 -199 mg/dl 
High: > 200 mg/dl 
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 TABLE 8: 
HDL DISTRIBUTION: 
              HDL Frequency Percent 
 Abnormal 32 33.3 
Normal 64 66.7 
Total 96 100.0 
 
 
Normal :> 50 
Hypercholesterolemia was found in 40.6% of patients . Among 96% 
patients, 39 cases had high total cholesterol values. Borderline high values 
were found in 18.8 % of patients. Mean cholesterol value of  213 mg/dl 
ranging from minimum of 119 to 310 mg/dl.  
 
Abnormal 
33% 
Normal 
67% 
HDLrange 
 LDL was elevated in 42.7% of cases. Among 96 cases ,41 patients 
had elevated LDL levels more than 160 mg/dl. Borderline high LDL values 
were found in 14.6%. The mean LDL value was 139 mg/dl ranging from 
minimum of 76 to 290 mg/dl. 
 
Triglyceride was elevated in only 27.1% . Among 96 cases, only 26 
cases had high triglyceride values. Mean triglyceride value of 121.3 mg/dl 
ranging from minimum of 76 to 222 mg/dl 
 
HDL values were found to be normal in 66.7% of cases .the mean 
HDL was 51.9 mg/dl ranging from minimum of 33 to 70 mg/dl. 
  
  
DESCRIPTIVE STATISTICS: 
 
 
N Minimum Maximum Mean 
Std. 
Deviation 
AGE 96 11 60 41.33 10.945 
 
 
TSH 96 0.0 25.0 12.356 5.7581 
 
 
BMI 96 17 29 21.84 2.785 
 
 
TOTAL 
CHOLESTEROL 
96 119 310 213.81 47.692 
 
 
 
LDL 96 76 290 139.00 41.884 
 
 
 
 
TRIGLYCERIDES 96 76 222 121.39 42.650 
 
 
 
HDL 96 3 70 51.99 10.368 
 
 
  
  
CORRELATION TABLES 
TABLE 1: 
CORRELATION BETWEEN TSH AND BMI 
 
 
 TSH range Total 
< 10 10 - 20 > 20 
BMI range Lean Count 12 11 1 24 
 % within 
TSH range 
25.5% 33.3% 6.3% 25.0% 
Non 
Obese 
Count 30 17 12 59 
 % within 
TSH range 
63.8% 51.5% 75.0% 61.5% 
Obese Count 5 5 3 13 
 % within 
TSH range 
10.6% 15.2% 18.8% 13.5% 
Total Count 47 33 16 96 
% within 
TSH range 
100.0% 100.0% 100.0% 100.0% 
 
 
 
 
  
 
 
 
There exists a statistical correlation between rising TSH levels and 
increased BMI status. The correlation is not statistically significant with p 
value > 0.05 and x^2 value of 0.298. 
  
< 10 10 - 20 > 20 
BMIrange with TSHrange 
Lean Non Obese Obese 
  
 
TABLE 2: 
CORRELATION BETWEEN TSH AND TOTAL CHOLESTEROL 
 
TOTAL CHOLESTEROL TSH range Total 
< 10 10 - 20 > 20 
TC 
range 
Normal Count 29 10 0 39 
 % within TSH 
range 
61.7% 30.3% 0.0% 40.6% 
Borderline Count 11 7 0 18 
 % within TSH 
range 
23.4% 21.2% 0.0% 18.8% 
High Count 7 16 16 39 
 % within TSH 
range 
14.9% 48.5% 100.0% 40.6% 
 
Total 
Count 47 33 16 96 
     
% within TSH 
range 
100.0% 100.0% 100.0% 100.0% 
 
 
 
 
  
 
 
P value : 0.000                   x^ 2  : 0.000 
 
There exists correlation between rising TSH levels and total 
cholesterol in patients with subclinical hypothyroidism. The relation is 
statistically significant with a p value of 0.001 
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TABLE 3: 
CORRELATION BETWEEN TSH AND LDL : 
 
 
LDL RANGE 
 
TSHrange Total 
< 10 10 - 20 > 20 
LDLrange Normal Count 27 13 1 41 
% within 
TSHrange 
57.4% 39.4% 6.3% 42.7% 
Borderline Count 11 3 0 14 
% within 
TSHrange 
23.4% 9.1% 0.0% 14.6% 
High Count 9 17 15 41 
% within 
TSHrange 
19.1% 51.5% 93.8% 42.7% 
Total Count 47 33 16 96 
% within 
TSHrange 
100.0% 100.0% 100.0% 100.0% 
 
 
 
 
 
  
 
 
 
P value 0.000                       x^2  0.000 
 
There exists a relation between rising TSH and LDL levels .the 
correlation is statistically significant with a p value of 0.000 
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TABLE 4: 
CORRELATION BETWEEN TSH AND TRIGLYCERIDE: 
 
TSH RANGE 
TSHrange Total 
< 10 10 - 20 > 20 
 Normal Count 43 24 3 70 
% within 
TSHrange 
91.5% 72.7% 18.8% 72.9% 
Borderline Count 4 6 6 16 
% within 
TSHrange 
8.5% 
 
18.2% 37.5% 16.7% 
High Count 0 3 7 10 
% within 
TSHrange 
0.0% 9.1% 43.8% 10.4% 
Total Count 47 33 16 96 
% within 
TSHrange 
100.0% 100.0% 100.0% 100.0% 
 
 
 
 
 
  
 
 
 
 
There exists correlation between rising TSH values and rise in 
serum triglyceride levels. The correlation is statistically significant with a 
p value of 0.000 and x^2 value of  0.000  
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TABLE 5: 
CORRELATION BETWEEN TSH AND HDL: 
 
  TSHrange Total 
< 10 10 - 20 > 20 
HDLrange Abnormal Count 6 14 12 32 
 % within 
TSHrange 
12.8% 42.4% 75.0% 33.3% 
Normal Count 41 19 4 64 
 % within 
TSHrange 
87.2% 57.6% 25.0% 66.7% 
Total Count 47 33 16 96 
% within 
TSHrange 
100.0% 100.0% 100.0% 100.0% 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
There seems to exists some correlation between rising TSH and 
serum HDL levels. 
 DISCUSSION 
Subclinical hypothyroidism is an endocrine disorder, where the 
patients mostly has no or only few symptoms and signs for diagnosis, and 
the diagnosis is made from elevated serum THYROID STIMULATING 
HORMONE and the serum free T4 and free T3 levels are within the 
reference range. 
 
The diagnosis of subclinical hypothyroidism is important in the 
society, as the patients does not display any signs and symptoms consistent 
with thyroid dysfunction. So this necessitates, early dignosis and 
management of subclinical hypothyroidism as they may transform to true 
hypothyroidism  
 
The rate of conversion of subclinical hypothyroidism to overt is 
around 2 to 5% per year. Though subclinical hypothyroidism is 
asymptomatic,the consequences of subclinical hypothyroidism  warrants 
further evaluation and treatment. It includes 
 
 Insulin resistance 
 Obesity 
 Increase in total cholesterol and LDL levels 
  Increase in vascular intima and media 
thickness 
 Endothelial dysfunction 
 Increase in peripheral resistance 
 Decreased myocardial contractility 
 Neuropsychiatric manifestation 
 Infertility 
 
“In this study I screened patients for subclinical hypothyroidism and 
evaluation of dyslipidemia in these patients. Among 96 cases of subclinical 
hypothyroidism, 33% of them were found to be between age group of 46 to 
55 years.” The mean age of presentation was found to be 41.3 years, 
ranging from minimum of 11 years to maximum of 60 years. This 
prevalence rate increases as age increases. 
 
The BMI distribution among subclinical hypothyroidism has no 
correlation to serum TSH levels. Among 96 patients with subclinical 
hypothyroidism, 61.5% of patients had a normal BMI between 20 and 25 
kg/m^2 and 13.5% of patients had BMI beyond 25 kg/m^2. 
 
 In regard to the sex distribution of patients, it was clearly evident 
that the prevalence of subclinical hypothyroidism is more common among 
women. Among 96 cases of subclinical hypothyroidism, only 8 cases were 
men. 
 
On analyzing TSH distribution, it was found that among 96 cases, 
the mean TSH value was 12.3 mIU/l. The TSH values range from 
minimum of 5.8 mIU/l to maximum of 25mIU/l.  34% of the cases had 
TSH values between 10 and 20 mIU/l.(14 15 16,83) 
       
On analysing the lipid profile abnormalities , patients were subjected 
to fasting lipid profile comprising serum total cholesterol, serum 
triglyceride, serum HDL and serum LDL. The reference range of serum 
lipid profile;(1) 
 
Total cholesterol: 
 Normal : < 200 mg/dl 
 Borderline : 201 to 239 mg/dl  
 High  : > 240 mg/dl 
  
 LDL : 
 Normal ; <130 mg/dl  
 Borderline; 131 to 159 mg/dl 
 High : >160 mg/dl 
 
Triglcerides: 
 Normal : < 150 mg/dl  
 Borderline : 151 to 199 mg/dl  
 High ; > 200 mg/dl 
 
HDL: 
 Normal : > 50 mg/dl 
 Abnormal > 50 mg/dl 
 
Hypercholesterolemia was found in 40.6% of  patients. Among 
96% patients, 39 cases had high total cholesterol values. Borderline high 
values were found in 18.8% of patients. Mean cholesterol value of  213 
mg/dl ranging from minimum of 119 to 310 mg/dl.  
 LDL was elevated in 42.7% of cases. Among 96 cases, 41 patients 
had elevated LDL levels more than 160 mg/dl. Borderline high LDL values 
were found in 14.6%. The mean LDL value was 139 mg/dl ranging from 
minimum of 76 to 290 mg/dl. 
 
Triglyceride was elevated in only 27.1%. Among 96 cases, only 26 
cases had high triglyceride values. Mean triglyceride value of 121.3 mg/dl 
ranging from minimum of 76 to 222 mg/dl. 
 
HDL values were found to be normal in 66.7% of cases. The mean 
HDL was 51.9 mg/dl ranging from minimum of 33 to 70 mg/dl. 
 
Statistical analysis of Colorado thyroid prevalence study showed 
significant elevation of total cholesterol and LDL in subclinical 
hypothyroidism compared to euthyroid controls. A meta-analysis 
conducted to evaluate the effect of thyroxine treatment on the lipid profile 
in subclinical hypothyroidism has shown significant reduction in total 
cholesterol level and LDL levels. A study conducted in north India 
comprising 100 patients, in the age group of 15 to 60 years having 
 subclinical hypothyroidism were screened for lipid abnormalities. They 
were found to have significant elevations in triglyceride and VLDL levels 
and nominal increases in cholesterol and LDL levels. (73,74) 
 
There is no established evidence for lowering of serum lipid profile 
with replacement therapy. The meta-analysis conducted comprising 13 
studies showed a significant reduction in total cholesterol by 8 to 15 mg/dl 
and LDL by 10 mg/dl with thyroxine therapy. The triglyceride and HDL 
showed no significant changes.(77) 
 
The changes noted in lipid abnormalities depends on multiple 
variables like age, race, sex and pretreatment lipid values. In view of lipid 
abnormalities and its association with cardiovascular abnormalities it is 
important to investigate the effect of hormone on lipid profile in 
hypothyroidism. 
 
Among 96 patients, 39 patients had high total cholesterol values and 
18 cases were having borderline high total cholesterol values. It is 
important to note that among the 39 cases with high cholesterol values, 16 
 patients were having TSH between 10 to 20 mIU/l and other 16 of them 
were having TSH >20 mIU/l . 
 
Similarly among the 96 cases, 41 patients had high serum LDL 
levels and 14 had borderline high LDL levels .among those 41 patients 17 
of them were having TSH between 10 to 20 mIU/l and 15 of them were 
having TSH > 20 mIU/l. so TSH levels has significant correlation with 
total cholesterol and LDL levels . As the TSH level increases , the serum 
total cholesterol and LDL also increases.  
  
 CONCLUSIONS 
 
1. Increased prevalence of subclinical hypothyroidism among females. 
 
2. Increased prevalence of subclinical hypothyroidism beyond the age 
group of 50 years. 
 
3. 34 % of patients has TSH levels between 10 to 20 mIU/l. 
 
4. Significant elevations in total cholesterol and serum LDL in  
subclinical hypothyroidism  
 
5. Association of TSH with total cholesterol and LDL elevations 
 
6. No much significant changes in triglycerides and HDL levels. 
  
 SUMMARY 
Subclinical hypothyroidism is a condition where the thyroid gland 
is still producing adequate thyroid hormones and the early thyroid 
dysfunction is diagnosed with elevated serum thyroid stimulating 
hormone. On conversion to overt hypothyroidism , thyroid gland no longer 
produces adequate thyroid hormones. Thyroxine is a vital hormone that 
regulates body metabolism and balance. As single TSH value may be 
misguiding due to fluctuating levels over 24 hours, two TSH values in 2 to 
3 months interval is taken for diagnosis.(2,14) 
 
The risk of transformation to true hypothyroidism in  is seen with 
the following(10,3) 
 Females 
 Symptomatic patients  
 Presence of antithyroid antibodies 
 Presence of goiter 
 
 
 Consensus on the treatment of subclinical hypothyroidism varies 
among different physicians on keeping in mind the adverse lipid 
abnormalities and the cardiovascular abnormalities .So it is advisable to 
initiate treatment in subclinical hypothyroidism patient with long term 
TSH more than 10 mIU/l.  
 
After getting the institutional clearance and informed consent from 
the patient I selected 96 cases of subclinical hypothyroidism applying the 
inclusion and exclusion criteria in the study and evaluated there lipid 
abnormalities. Subclinical hypothyroidism is more common among 
females. Being a hospital based cross sectional study, most of the patients 
who attended the op departments were having symptoms .only few patients 
were screened randomly . 
 
High risk population Screening was most useful part of the study 
including;  
 Obesity 
 Infertility  
 Menstrual irregularities 
 Pregnancy 
  Presence of goiter 
 Mood disorders 
 Coarse hypothyroid facial features 
 
Those with lipid abnormalities, mostly benefits from treatment with 
thyroxine. So this study holds good in evaluating cases of lipid 
abnormalities in subclinical hypothyroidism. Appropriate follow of 
patients annually in untreated cases of subclinical hypothyroidism is 
essential for preventing the progression of the disease.(2,3,4) 
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 ABBREVIATIONS 
BMI  - Body mass index 
BP  - Blood pressure 
CHD  -  Coronary heart disease 
FBS   – Fasting blood sugar 
HDL   - High density lipoprotein 
I Q   - Intelligence quotient 
LDL   - Low density lipoprotein 
PAF   - Platelet activating factor 
PAF- AH - Platelet activating factor acetyl hydrolase 
RAI  - Radio active iodine 
T3   - Total triiodothyronine 
T4   – Total thyroxine 
fT4  - Free thyroxine 
TSH   – Thyroid stimulating hormone 
TRH   – Thyrotropin releasing hormone 
TPO   – Thyroid peroxidase 
TC   – Total cholesterol 
TG   - Triglycerides 
  
 APPENDIX I 
PROFORMA 
STUDY OF DYSLIPIDEMIA IN SUBCLINICAL 
HYPOTHYROIDISM 
Name                    Age                      Sex 
Address                  Occupation 
Phone 
DIAGNOSTIC CRITERIA 
Elevated TSH level(>4.5uIU/mL) with normal total or free T4 & T3 
Values 
SYMPTOMS 
Asymptomatic                               Tiredness 
Weightgain                                  Neck swelling 
Muscle weakness                            Depression 
Muscle cramps                              Cold intolerance 
Myalgia,                                    arthralgia                 
Anorexia 
Constipation                                Infertility 
PAST HISTORY 
CAD                 Dyslipidemia                   DM 
Hypertension         Autoimmune diseases          CRF 
 TB                   Thyroidectomy                 Asthma 
Severe nonthyroidal Illness                           Adrenal Failure 
Menstrual History: Menorrhagia                      Menopause 
Obstetric History : Infertility,                        miscarriages 
Treatment history: H/o: Drugs (Thyroxin / Lithium / 
Amiadarone,antithyroid,Interferon), Radio iodine ,H/o neck Radiation . 
Salt intake : Iodised / non iodised 
GENERAL EXAMINATION 
Built& Nourishment                      BMI                    Pallor 
Icterus/ Cyanosis /Clubbing /Edema/Lymphadenopathy/ 
Pulse rate                                 BP                      RR                           
Temperature                                     Peripheral pulses 
THYROID 
Diffuse/ Nodular //Thyroidectomy scar 
RESPIRATORY SYSTEM 
Pleural Effusion Other findings 
CVS 
Cardiomegaly/ Murmur 
MUSCULO SKELETAL 
Arthralgia- 
Myalgia 
 Stiffness /Carpel tunnel syndrome /Muscle weakness 
NERVOUS SYSTEM 
Neuropathy /Seizures 
Cerebellar signs /Delayed Relaxation of DTR 
ALIMENTARY SYSTEM 
OTHERS 
Periorbital Puffiness            Dry, CoarseSkin                
Ichthyosis 
Macroglossia                   Loss of Hair 
INVESTIGATIONS 
Urine - Albumin , Sugar , Casts , RBC 
FBS, PPBS, Blood Urea , Serum Creatinine 
TFT- T3 T4,fT4,Ft3,TSH 
TOTAL CHOLESTEROL, LDL, HDL ,TG. 
 
 
 
 
 
 
 MASTER CHART  
NAME AGE SEX TSH BMI TOTAL 
CHOLESTEROL 
LDL TRIGLYCERIDES HDL  
ANJALAI 42 F 21.2 230 100 96 52    
SEKAR 46 M 6.8 27 210 133 98 56  
RANI 41 F 15.4 23.6 245 162 110 60  
MEERA 19 F 13.5 18 242 166 152 48  
BHAVANI 22 F 5.9 22 150 96 88 58  
VASANTHA 46 F 21.6 24.6 256 168 210 44  
MARIYAMMAL 36 F 6.9 21.1 206 108 92 62  
PUSHPA 42 F 21 23.6 261 170 160 41  
SHIVAMANI 33 F 12.5 19.4 210 110 94 54  
VADANI 34 F 8.9 21.6 192 114 96 51  
KAVERI 42 F 12.4 26 196 116 92 56  
RANI 53 F 22.5 22.4 272 166 140 46  
SAVITHRI 39 F 12.8 18.2 172 96 116 52  
KALYANI 48 F 12 21.2 142 98 136 60  
KANCHANA 31 F 7.8 19 167 88 112 62  
PRIYA 46 F 23.5 25 300 172 216 42  
FATHIMA 11 F 9 22.2 156 86 99 57  
MANGAI 38 F 22 25.6 310 190 220 33  
DEVI 26 F 17 18.5 216 124 96 56  
PARVATHAM 53 F 11 20 180 110 88 58  
SAROJA 42 F 10.5 24 146 99 90 54  
GAYATHRI 28 F 11.6 21.6 132 104 80 60  
PUNITHA 35 F 15.8 21.4 247 166 82 54  
RAVI 29 M 6.9 17 138 110 96 58  
SANGAVI 31 F 15.7 28 248 160 158 59  
KALYANI 46 F 7.8 21.1 169 114 90 54  
NANDHANAM 55 F 24.5 24.2 280 168 208 40  
LINSY 29 F 12.1 16.6 182 116 88 60  
KUTTIYAMAL 54 F 12.7 23.6 246 156 106 43  
ANANDHI 36 F 8.7 20.6 193 120 102 61  
SASIKALA 43 F 13.2 28 252 162 112 42  
DHARANI 24 F 15 21.2 234 166 112 42  
RANGAMA 56 F 15.4 19.8 181 106 109 59  
DEVI 25 F 20.1 20.3 260 106 160 38  
KALYANI 48 F 25 28.5 271 176 216 39  
SAROJA 60 F 9.6 26 190 110 110 56  
MUNIYAMMA 59 F 16.5 20.1 246 168 112 42  
MALLIGA 52 F 12.5 18.2 129 86 90 54  
 ARUNA 49 F 20.6 20.5 278 162 116 53  
SRIDEVI 37 F 6 20.9 119 80 86 52  
REVATHY 42 F 12.5 16.9 182 89 96 61  
KALA 43 F 20.8 22.1 256 165 166 32  
RANI 48 F 7.8 20.2 180 90 86 62  
THANGAMANI 49 F 18.4 21.3 262 174 168 39  
KALAIVANI 42 F 8.7 19.6 230 135 104 58  
KONDAMA 44 F 8.9 23.2 122 90 84 59  
RAJU 46 M 9.6 22.4 212 136 82 56  
SALIMA 14 F 14.4 26 248 169 98 45  
DEVI 46 F 6.6 20 146 86 76 51  
SELVAM 52 M 17.5 24.6 232 160 92 58  
GAYATHRI 36 M 7.6 26.2 154 92 82 59  
ROJA 42 F 9 20.9 141 96 76 60  
ROSY 21 F 5.8 17.6 171 102 98 62  
MALLIGA 58 F 11.5 23.2 211 140 101 54  
MADHAVI 34 F 19.3 18.6 260 178 218 36  
MANJU 24 F 8.7 26.1 167 140 140 56  
MUTHU 36 M 21.4 22.1 276 192 171 40  
KUPPAMAL 58 F 6.7 21.2 146 76 99 57  
SAROJA 56 F 16.5 20.3 260 166 172 44  
VALLI 46 F 8.7 20.8 170 99 101 55  
KOMALA 42 F 16.8 21.2 242 158 104 41  
KAVITHA 32 F 7.8 23.3 186 101 108 59  
NALINI 42 F 7.6 17.5 248 160 162 54  
USHA 46 F 14.3 24.2 252 162 166 45  
PIARREBEE 43 F 8.7 28 248 158 111 41  
AMULU 55 F 9.8 19.2 162 112 99 56  
AKILA 16 F 8.8 20.2 243 163 105 46  
DEVIKA 48 F 6.9 19.8 215 155 112 58  
ASWINI 27 F 6.4 25 259 171 170 34  
SETTU 42 M 13.4 27.3 262 179 216 36  
THULASI 44 F 5.8 20.1 154 102 112 60  
SHYAMALA 46 F 22.5 24.3 310 290 222 38  
ANDAL 59 F 21.9 20 248 276 167 66  
SAROJA 53 F 8.7 20.2 182 110 94 70  
KALYANI 42 F 8.6 20.6 217 165 101 40  
NAGAMMA 46 F 14.4 21.3 260 170 176 38  
PUNITHA 41 F 24 28.2 271 276 180 56  
DHIVYA 23 F 6.8 21.4 190 138 93 60  
SEETHA 41 F 22.1 21.2 279 174 219 40  
MEENA 35 F 8.7 21.1 222 140 101 66  
SURESH 46 M 5.9 20.4 234 136 90 62  
SATHYA 42 F 7.9 19.4 242 160 162 54  
 MALA 48 F 7.6 21.6 181 96 90 54  
RANI 52 F 5.9 22.3 239 162 101 66  
BHAVANI 42 F 18.6 19.8 260 180 109 46  
SASIKALA 46 F 6.9 21.2 136 78 86 68  
PUVI 26 F 6.9 21.5 234 169 94 64  
SHEELA 42 F 11.3 23.1 210 131 76 54  
MAHALAKSHMI 46 F 17.6 20.6 260 171 210 41  
RUPA 29 F 7 20 142 76 78 55  
SAROJA 42 F 8.9 20.4 220 169 98 38  
MUNIYAMMA 58 F 7.8 23.6 168 96 86 58  
MARI 48 F 8.7 18.6 248 167 160 56  
MALLIGA 49 F 24.7 24.2 256 162 76 59  
SAVITHA 56 F 8.6 22.4 180 100 90 66  
SAROJA 50 F 6.9 18.2 186 148 85 64  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
